CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Becky Kamowitz was appointed executive director of The Skin Cancer Foundation in January 2025. She talks about the ...

The Philadelphia Eagles have had their eyes on this game and more since they fell apart at the end of last season. This has been their reason for every move they made in the offseason. They felt ...

A university building evacuated, a hapless driver rescued, shipping paused, and thousands without power as emergency and utility crews work around the clock responding to countless calls for help.

Nintendo has finally revealed its new console, Nintendo Switch 2, and we’ve published the first images in a gallery below. In a Nintendo Switch 2 reveal video published on Thursday, the platform ...

Trump later seized on what appeared at the time to be a good-natured exchange to promote his “Fight, Fight, Fight” line of colognes. He shared a photo of himself and Biden on social media alongside ...

The fires continue to burn, and the full extent of the damage is still unknown. These latest photos show what's left of places thousands of people call home: What caused the massive blaze in ...

The filmmaker possessed a singular vision — and a knack for finding collaborators who could convey it. The filmmaker possessed a singular vision — and a knack for finding collaborators who ...

Nintendo has finally lifted the lid on Switch 2 and... well, it looks an awful lot like the Switch. But there are subtle differences, a few obvious new additions, and still some intriguing ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...